title: Intense Pulsed Light Pulse Configuration Manipulation Can Resolve the Classic Conflict Between Safety and Efficacy.
abstract: The widely used intense pulse light (IPL) technology was first commercially launched to the medical market in 1994 and similar to lasers, is based on the basic principle of selective photothermolysis. The main conflict during treatments with light-based technologies is between safety and efficacy of the treatment. The aim of this study was to evaluate new IPL technology, which integrates three different pulse configurations, with specific attention on the safety and efficacy of the treatment. 101 volunteers (with Fitzpatrick skin types I-VI) were treated as follows: 9 patients underwent 8 bi-weekly acne clearance treatments, 51 patients underwent 6-12 hair removal treatments, 11 patients were treated for general skin rejuvenation, 15 patients were treated for pigmentation lesions, and 15 patients were treated for vascular lesions. No serious adverse events were recorded. All patients that were treated for hair removal achieved significant hair clearance. The patients with facial rosacea responded the fastest to the treatment. Eight of nine patients that were treated for acne clearance achieved significant reduction in acne appearance. The results represented in this study support the approach that when taking into consideration both efficacy of the treatment and safety of the patients, the system should be "flexible" enough to allow exact treatment settings profile for each patient, according to their skin type and the symptom's biophysical characteristics. <
authors.forename: Inna
authors.initials: I
authors.lastname: Belenky
authors.forename: Cruzy
authors.initials: C
authors.lastname: Tagger
authors.forename: Andrea
authors.initials: A
authors.lastname: Bingham
mesh_terms: D000152:Acne Vulgaris / Q000473:pathology / Q000628:therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006204:Hair Removal / Q000379:methods*; D006801:Humans; D062325:Intense Pulsed Light Therapy / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010859:Pigmentation Disorders / Q000473:pathology / Q000628:therapy; D012060:Rejuvenation; D012393:Rosacea / Q000473:pathology / Q000628:therapy; D012867:Skin / Q000378:metabolism / Q000473:pathology; D015595:Skin Aging; D012871:Skin Diseases / Q000473:pathology / Q000628:therapy*; D017445:Skin Diseases, Vascular / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome; D055815:Young Adult